VIENNA—Botulinum toxin type A (BTA) injected into the prostate may be a safe and effective treatment for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), according to preliminary study results presented here at the 26th Annual Congress of the European Association of Urology.
VIENNA—Findings from a large randomized trial confirm the effectiveness of botulinum toxin type A (BoNT-A) for refractory idiopathic detrusor overactivity (IDO) in women.
VIENNA—Metabolic syndrome is associated with an increased risk of high-grade prostate cancer (PCa) among men with a positive prostate biopsy, a study found.
VIENNA—One year after undergoing living donor nephrectomy (LDN), more than half of donors will have chronic kidney disease (CKD), according to a British study. Their decline in renal function, however, appears to remain stable for at least five years and patients rarely suffer adverse cardiovascular events and cardiac mortality.
